Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010781 | 0.92 | ELANE (0.44) | PPARGELANETP53THRBSMN1; SMN2 | |
| SCHEMBL3002052 | 0.89 | PPARG (0.45) | PPARGPPARA | |
| SCHEMBL3007687 | 0.86 | PPARG (0.45) | PPARGTP53THRBSMN1; SMN2MAPT | |
| SCHEMBL4781515 | 0.84 | SLC5A1 (0.42) | PPARGELANETP53THRBSMN1; SMN2 | |
| SCHEMBL4914794 | 0.84 | PTGES (0.46) | PPARGTP53THRBSMN1; SMN2PPARA | |
| SCHEMBL4923129 | 0.83 | ELANE (0.43) | PPARGELANETP53THRBSMN1; SMN2 | |
| SCHEMBL4918420 | 0.82 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL3014883 | 0.81 | PPARG (0.50) | PPARGPPARA | |
| SCHEMBL3011861 | 0.81 | MEN1 (0.51) | TP53THRBSMN1; SMN2MAPTPOLB | |
| SCHEMBL3013050 | 0.80 | MAPT (0.49) | TP53THRBSMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | PPARG 2505/4885ELANE 790/4885TP53 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.